Registered Kenya · PPB

OXOFERIN SOLUTION

TETRACHLORODECAOXIDE

H2022/CTD8868/18641 EACH 100ML CONTAINS: TCDO FORMING “REACTION PRODUCT” WITH BIOLOGICAL ACTIVITY: 138.0 X 10^6 PMOL GENERIC/BIOSIMILARS

What it does

Tetrachlorodecaoxide is a chemical compound that may be used in specific medical applications.

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.

Source this medicine

Registration & product details

Registration no.
H2022/CTD8868/18641
Registration date
-
Expiry date
2027 September 12
Status
Registered
Active ingredient
TETRACHLORODECAOXIDE
Dosage form
EACH 100ML CONTAINS: TCDO FORMING “REACTION PRODUCT” WITH BIOLOGICAL ACTIVITY: 138.0 X 10^6 PMOL
Strength
-
Pack size
PACKED IN 50ML WHITE OPAQUE ROUND PLASTIC BOTTLE MADE UP OF H.D.P.E WITH PLASTIC PLUG AND BLUE COLORED PLASTIC CAP AND STICKER LABEL, FURTHER PACKED IN CARTON WITH INSERT
Therapeutic class
GENERIC/BIOSIMILARS
Manufacturer / MAH
Harleys
Applicant / LTR
BROOKES PHARMA PVT LIMITED
Country of origin
FOREIGN
Manufacturer location
63 Westlands Rd, Nairobi, Kenya

Source: Pharmacy and Poisons Board · fetched 2026-01-28 19:53:18 · updated 2026-09-25 02:27:25

Disclaimer: This information is sourced from Pharmacy and Poisons Board (Kenya). Always consult a qualified healthcare professional before using any medication.

About this medicine

Tetrachlorodecaoxide is a chemical compound that may be used in specific medical applications.

How it works

The exact way tetrachlorodecaoxide works in the body isn't fully understood.

Who it's for

This medication is typically used under special circumstances as advised by a healthcare professional.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: tetrachlorodecaoxide

BNF-referenced

Tetrachlorodecaoxide (TCDO) is a synthetic compound, specifically formulated as WF 10, which is a 1:10 dilution intended for intravenous administration. It was developed as an adjunctive therapy for patients with AIDS, especially those on combination antiretroviral therapy and those requiring prophylaxis against opportunistic infections. The drug is designed to target macrophages, thereby influencing immune responses and modulating inflammatory reactions.

Indications

  • AIDS
  • Opportunistic infection prophylaxis
  • Adjunctive therapy in combination with antiretroviral regimens

Dosage

Children: Refer to BNF for Children for specific dosing in paediatrics.

Adults: Refer to BNF for specific dosing in adults.

Mechanism of action

Tetrachlorodecaoxide acts primarily by targeting macrophages, which are crucial components of the immune system. It modulates immune responses by downregulating inappropriate inflammatory reactions, both in vitro and in vivo. This modulation may aid in improving the immune status of patients suffering from diseases such as AIDS.

Pharmacodynamics

The pharmacodynamics of TCDO involve its interaction with immune cells, particularly macrophages, leading to a modulation of the immune response. By downregulating inflammatory mediators, TCDO may help in reducing excessive immune activation and inflammation, which is often observed in patients with AIDS and during opportunistic infections.

Pharmacokinetics

The pharmacokinetics of tetrachlorodecaoxide are not well documented in the literature. General principles of pharmacokinetics suggest that intravenous administration allows for rapid distribution in the body. However, specific data regarding absorption, distribution, metabolism, and excretion are limited and should be referred to in clinical guidelines and literature.

Pregnancy

There is limited data on the use of tetrachlorodecaoxide during pregnancy. Consult relevant guidelines and consider the potential risks versus benefits.

Breast-feeding

Limited data available on the excretion of tetrachlorodecaoxide in human milk. Exercise caution and consider the potential risks versus benefits.

Storage

Store at room temperature, away from direct sunlight and moisture. Keep out of reach of children.

Formulations

  • WF 10 (1:10 dilution of tetrachlorodecaoxide for intravenous injection)
PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: tetrachlorodecaoxide

PubChem CID 3000391

Molecular formula: Cl4H2O11-4

Mechanism of action

WF 10 is a 1: 10 dilution of tetrachlorodecaoxide (TCDO) formulated for intravenous injection. It was developed by Oxo Chemie in Switzerland as an adjunctive therapy to combination antiretroviral and opportunistic infection prophylaxis regimens in AIDS patients. WF 10 specifically targets macrophages. WF10 potentially modulates disease-related up-regulation of immune responses both in vitro and in vivo. Thus immune response is influenced in a way that inappropriate inflammatory reactions are downregulated.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.

Ghana 1 product
Tanzania 1 product